Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus.1
Authors:
- Donald E. HricikDHDonald E. Hricik
- Thomas C. KnaussTKThomas C. Knauss
- Kenneth A. BodziakKBKenneth A. Bodziak
- Kelly WeigelKWKelly Weigel
- Victoria RodriguezVRVictoria Rodriguez
- David SeamanDSDavid Seaman
- Christopher SiegelCSChristopher Siegel
- John ValenteJVJohn Valente
- James A. SchulakJSJames A. Schulak
- 1 September 2003
- journal article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 76 (6) , 938-942
Abstract
Withdrawal of corticosteroids from the immunosuppressive regimens of kidney transplant recipients has been associated with an increased risk of acute and chronic allograft rejection. Previous studies indicate that the risk of rejection is particularly high in African Americans. We prospectively enrolled 44 African American kidney transplant recipients to participate in an uncontrolled trial in which they were initially treated with sirolimus, tacrolimus, and corticosteroids. No patient received antibody induction therapy. Prednisone was withdrawn from eligible patients free of acute rejection beginning as early as 3 months posttransplant, and followed for a minimum of 9 months posttransplant. Patients were followed for acute rejection and for changes in blood pressure, body weight, and serum creatinine concentrations before and after withdrawal of steroids. Thirty of 44 patients (68%) were weaned off of prednisone. Follow-up after withdrawal of prednisone ranged from 3 to 26 months (mean, 14.3+/-7.7 months). Two of 30 patients (6.7%) developed acute rejection. At last follow-up, 27 of 30 patients (90%) remain steroid-free. Steroid withdrawal was associated with significant reductions in blood pressure. Use of sirolimus and tacrolimus, without the use of induction antibody therapy, allows withdrawal of prednisone as early as 3 months posttransplant with low rates of subsequent acute rejection in African American kidney transplant recipients. Withdrawal of prednisone was associated with lower blood pressures and the need for fewer antihypertensive medications.Keywords
This publication has 14 references indexed in Scilit:
- Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroidsTransplantation, 2002
- Steroid-free Immunosuppression in Kidney Transplantation: An Editorial ReviewAmerican Journal of Transplantation, 2002
- Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive RegimenNew England Journal of Medicine, 2000
- Sirolimus-tacrolimus combination immunosuppressionThe Lancet, 2000
- Relationships between arterial hypertension and renal allograft survival in African-American patientsAmerican Journal of Kidney Diseases, 1997
- Corticosteroids in Kidney Transplant RecipientsDrug Safety, 1995
- VARIABLE EFFECTS OF STEROID WITHDRAWAL ON BLOOD PRESSURE REDUCTION IN CYCLOSPORINE-TREATED RENAL TRANSPLANT RECIPIENTSTransplantation, 1992
- WITHDRAWAL OF STEROIDS AFTER RENAL TRANSPLANTATION—CLINICAL PREDICTORS OF OUTCOME1Transplantation, 1992
- Independent Effects of Cyclosporine and Prednisone on Posttransplant HypercholesterolemiaAmerican Journal of Kidney Diseases, 1991
- COMPLETE REPLACEMENT OF METHYLPREDNISOLONE BY AZATHIOPRINE IN CYCLOSPORINE-TREATED PRIMARY CADAVERIC RENAL TRANSPLANT RECIPIENTS1 Pressented at the 6th Annual Meeting of the American Society of Transplant Physicians, May 1987, Chicago, ILTransplantation, 1988